1-6 of 6
David T. Dicker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

Marie D. Ralff, Christina L.B. Kline, Ozan C. Küçükkase, Jessica Wagner, Bora Lim, David T. Dicker, Varun V. Prabhu, Wolfgang Oster, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (7): 1290–1298.
https://doi.org/10.1158/1535-7163.MCT-17-0121
Published: 04 July 2017
View article titled, ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
Open the PDF for ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms in another window
Includes: Supplementary data
Journal Articles

Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells

Marie D. Baumeister, Jessica Wagner, Christina L.B. Kline, Joshua E. Allen, David T. Dicker, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-A16.
https://doi.org/10.1158/1535-7163.TARG-15-LB-A16
Published: 01 December 2015
View article titled, Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells
Journal Articles

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Nathan G. Dolloff, Joshua E. Allen, David T. Dicker, Nicole Aqui, Dan Vogl, Jozef Malysz, Giampaolo Talamo, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2321–2330.
https://doi.org/10.1158/1535-7163.MCT-12-0578
Published: 08 November 2012
View article titled, Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Open the PDF for Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9 in another window
Includes: Supplementary data
Journal Articles

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

Joshua E. Allen, Roger Ferrini, David T. Dicker, Glenda Batzer, Elise Chen, Daniela I. Oltean, Bing Lin, Mark W. Renshaw, Anke Kretz-Rommel, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2087–2095.
https://doi.org/10.1158/1535-7163.MCT-12-0366
Published: 09 October 2012
View article titled, Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Open the PDF for Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes in another window
Includes: Supplementary data
Journal Articles

Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.

Nathan G. Dolloff, Giampaolo Talamo, David T. Dicker, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C77.
https://doi.org/10.1158/1535-7163.TARG-11-C77
Published: 12 November 2011
View article titled, Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.
Journal Articles

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells

Jay F. Dorsey, Akiva Mintz, Xiaobing Tian, Melissa L. Dowling, John P. Plastaras, David T. Dicker, Gary D. Kao, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12): 3285–3295.
https://doi.org/10.1158/1535-7163.MCT-09-0415
Published: 09 December 2009
View article titled, Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative <em>in vivo</em> effects against glioblastoma multiforme cells
Open the PDF for Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative <em>in vivo</em> effects against glioblastoma multiforme cells in another window
Includes: Supplementary data